Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Holding Corporation

Scholar Rock Holding (($SRRK)) has held its Q1 earnings call. Read on for the main highlights of the call. Scholar Rock’s latest earnings call stru...

Scholar Rock Charts High-Stakes Path to SMA Launch

Citi analyst Geoff Meacham maintained a Buy rating on Scholar Rock Holding on May 7 and set a price target of $58.00. The company’s shares closed l...

Citi Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Scholar Rock Holding on May 8 and set a price target of $58.00. The comp...

Bank of America Securities Sticks to Their Buy Rating for Scholar Rock Holding (SRRK)

In a report released today, Gary Nachman from Canaccord Genuity maintained a Buy rating on Scholar Rock Holding, with a price target of $62.00. Acc...

Canaccord Genuity Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Scholar Rock Holding today and set a price target of $65.00. According to TipRanks, Ka...

Evercore ISI Sticks to Its Buy Rating for Scholar Rock Holding (SRRK)

Barclays analyst Etzer Darout maintained a Buy rating on Scholar Rock Holding today and set a price target of $55.00. Darout covers the Healthcare ...

Barclays Remains a Buy on Scholar Rock Holding (SRRK)

Scholar Rock Holding ( ($SRRK) ) has shared an announcement. Scholar Rock on May 7, 2026 reported first-quarter 2026 results and recent milestones,...

Current Quarter	$-0.86	Next Quarter	$-0.88
Current Year	$-3.18	Next Year	$-2.73
QoQ Growth	-2.3%	YoY Growth	+14.2%
3Y EPS CAGR	-13.3%	Target Price	$59.07
Consensus	Buy	Upside	+14.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SRRK	$51.51	+7.02%	2.65M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SRRK	$51.51	+7.0%	2.65M
3
4
5
6

SRRK

SRRK

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Scholar Rock Holding Corporation Data in Excel

Get Scholar Rock Holding Corporation Data in Excel